Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:REPL

Replimune Group Q2 2027 Earnings Date & Estimates

Replimune Group logo
$11.99 +0.27 (+2.30%)
Closing price 10/22/2026 04:00 PM Eastern
Extended Trading
$11.92 -0.08 (-0.63%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group is estimated to report Q2 2027 earnings on Wednesday, October 28, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q2 2027
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Replimune Group in Q2 2027

Replimune Group is expected to post earnings of -$0.7840 per share on revenue of $1.00 million. In the same quarter a year earlier Replimune Group reported -$0.90 per share. Replimune Group last reported on August 14, 2026, posting -$0.72 per share and missing the -$0.6940 consensus estimate. Replimune Group has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.7840
Expected Revenue
$1.00 million
Prior-Year EPS
-$0.90

Recent Track Record

Last Reported
Q1 2027
Last Quarter EPS
-$0.72 (Missed by -$0.0260)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q2 2027 Call

Replimune Group Q2 2027 Earnings FAQ

Replimune Group (NASDAQ:REPL) is estimated to report Q2 2027 earnings on Wednesday, October 28, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Replimune Group's Q2 2027 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Replimune Group to post earnings of -$0.7840 per share for Q2 2027.

The consensus revenue estimate for Replimune Group is $1.00 million for Q2 2027.

Replimune Group Earnings Headlines

Replimune Group (REPL) Projected to Post Earnings on Wednesday
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148245
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
October 22 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386248/0/en/replimune-to-report-the-fiscal-second-quarter-2027-financial-results-and-provide-corporate-update-on-october-28-2026.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
 |  Base Camp Trading (Ad)
Replimune Group (REPL) Stock Looks Rich After A 141% Run
October 17, 2026  |  sg.finance.yahoo.comhttps://sg.finance.yahoo.com/news/replimune-group-repl-stock-looks-161448106.html
Replimune Group, Inc. (NASDAQ:REPL) Stock Has Consensus Target Price of $12.00
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114069
Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/replimune-group-repl-launches-tudriqev-151227981.html
See More Replimune Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email.

About Replimune Group

Replimune Group (NASDAQ:REPL) is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity. The company is evaluating RP1 in clinical trials for multiple solid tumors, including advanced melanoma, both as a standalone treatment and in combination with other immunotherapies. Replimune is also developing additional candidates, including RP2 and RP3, which are designed to build on the company’s tumor-selective viral platform.

Founded in 2015, Replimune is headquartered in Woburn, Massachusetts, and serves the global biopharmaceutical and oncology markets through its research and clinical-development programs. The company’s leadership has included Philip Astley-Sparke as chief executive officer, and its shares trade on the Nasdaq under the symbol REPL.

View Replimune Group Profile
Earnings Tools